Volume 16, Issue 1 pp. 149-155
Original Article
Free Access

Defective methionine metabolism in cirrhosis: Relation to severity of liver disease

Professor Giulio Marchesini M.D.

Corresponding Author

Professor Giulio Marchesini M.D.

Istituto di Clinica Medica Generale e Terapia Medica, Università di Bologna, I-40138 Bologna, Italy

Istituto di Clinica Medica Generale e Terapia Medica, Università di Bologna, Policlinico S. Orsola, Via Massarenti 9, I-40138 Bologna, Italy===Search for more papers by this author
Elisabetta Bugianesi

Elisabetta Bugianesi

Istituto di Clinica Medica Generale e Terapia Medica, Università di Bologna, I-40138 Bologna, Italy

Search for more papers by this author
Giampaolo Bianchi

Giampaolo Bianchi

Istituto di Clinica Medica Generale e Terapia Medica, Università di Bologna, I-40138 Bologna, Italy

Search for more papers by this author
Andrea Fabbri

Andrea Fabbri

Istituto di Clinica Medica Generale e Terapia Medica, Università di Bologna, I-40138 Bologna, Italy

Search for more papers by this author
Elisabetta Marchi

Elisabetta Marchi

Istituto di Clinica Medica Generale e Terapia Medica, Università di Bologna, I-40138 Bologna, Italy

Search for more papers by this author
Marco Zoli

Marco Zoli

Istituto di Clinica Medica Generale e Terapia Medica, Università di Bologna, I-40138 Bologna, Italy

Search for more papers by this author
Emilio Pisi

Emilio Pisi

Istituto di Clinica Medica Generale e Terapia Medica, Università di Bologna, I-40138 Bologna, Italy

Search for more papers by this author
First published: July 1992
Citations: 55

Abstract

A block in the transsulfuration pathway has previously been suggested in cirrhosis on the basis of increased fasting methionine concentrations, decreased methionine elimination and low levels of methionine end products. To date, methionine elimination has never been studied under controlled steady-state conditions, and the relation of the severity of liver disease to impaired methionine metabolism has not been clarified. We measured methionine plasma clearance in 6 control subjects and in 12 patients with cirrhosis during steady-state conditions obtained by a primed, continuous methionine infusion. In the presence of high-normal fasting methionine concentrations (range = 14 to 69 μmol ± L−1 in controls and 26 to 151 μmol ± L−1 in cirrhotic patients), methionine plasma clearance was reduced in cirrhotic patients (2.25 ± S.D. 0.43 ml ± sec−1 vs. 2.86 ± S.D. 0.43 ml ± sec−1 in controls; p < 0.05), whereas methionine half-life was increased (282 ± 90 min vs. 187 ± 25 min in controls; p <0.05). Fasting methionine significantly correlated with methionine clearance. The infused methionine was not degraded to urea to any significant extent in cirrhotic patients, whereas a threefold increase in urinary urea nitrogen excretion rate was observed in controls. Similarly, taurine concentrations significantly increased both in plasma and in the urine in controls but not in cirrhotic patients. In cirrhotic patients methionine plasma clearance significantly correlated with galactose elimination capacity (r = 0.818) and with the Child-Pugh score (rs = −0.795). The study supports a major role of impaired liver cell function in the reduced metabolism of methionine and decreased formation of methionine end products that occur in cirrhosis. Impaired methionine metabolism is probably the basis for the hypermethioninemia of advanced cirrhosis. (HEPATOLOGY 1992;16:149–155.)

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.